Melatonin ameliorates microvessel abnormalities in the cerebral cortex and hippocampus in a rat model of Alzheimer’s disease

Pan Wang¹,²,³, Hai-Juan Sui²,⁴, Xiao-Jia Li²,³, Li-Na Bai²,³, Jing Bi²,³,*, Hong Lai¹,*

Abstract

Melatonin can attenuate cardiac microvascular ischemia/reperfusion injury, but it remains unclear whether melatonin can also ameliorate cerebral microvascular abnormalities. Rat models of Alzheimer’s disease were established by six intracerebroventricular injections of amyloid-beta 1–42, administered once every other day. Melatonin (30 mg/kg) was intraperitoneally administered for 13 successive days, with the first dose given 24 hours prior to the first administration of amyloid-beta 1–42. Melatonin ameliorated learning and memory impairments in the Morris water maze test, improved the morphology of microvessels in the cerebral cortex and hippocampus, increased microvessel density, alleviated pathological injuries of cerebral neurons, and decreased the expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2. These findings suggest that melatonin can improve microvessel abnormalities in the cerebral cortex and hippocampus by lowering the expression of vascular endothelial growth factor and its receptors, thereby improving the cognitive function of patients with Alzheimer’s disease. This study was approved by the Animal Care and Use Committee of Jinzhou Medical University, China (approval No. 2019015) on December 6, 2018.

Key Words: Alzheimer’s disease; brain; central nervous system; factor; in vivo; model; pathways; protein; rat

Chinese Library Classification No. R453; R741; Q576

Introduction

Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders affecting the aging population. The clinical manifestations of AD feature memory impairment, cognitive deficits, and behavioral problems (Reisberg et al., 1987). The disease, first described by Alois Alzheimer in 1907, is characterized by two major pathological hallmarks: enhanced cerebral depositions of amyloid-beta (Aβ) aggregates (Oddo et al., 2003; Zhang et al., 2018) and intraneuronal neurofibrillary tangles, which mainly comprise hyper-phosphorylated tau, a microtubule-associated protein (Rudrabhatla et al., 2011; Mamun et al., 2020; Wang et al., 2020). In addition, this degenerative disease is further characterized by chronic inflammation, neuronal dysfunction, loss of neurons and synaptic stabilization proteins (Lauterborn et al., 2011), and abnormal alterations of brain vascularization (Cai et al., 2015). Although many studies have attempted to decipher the mechanism of AD pathogenesis, its cause remains elusive. A putative factor that may be involved in vascular alterations in AD is vascular endothelial growth factor (VEGF). In the central nervous system, VEGF is involved in neural development (Hohman et al., 2015), angiogenesis (Robinson...
and Stringer, 2001; Greenberg and Jin, 2005; Cho et al., 2017; Wang et al., 2018), and vascular cell permeability (Koch and Claessen-Welsh, 2012; Chakraborty et al., 2018; Zhang et al., 2018). Many researchers have reported that VEGF is upregulated in response to hypoxia (Pham et al., 2002; Kim et al., 2017) and is elevated in the hypoperfused cortex and white matter in vascular dementia and AD (Tarkowski et al., 2002; Thomas et al., 2015). Both VEGF and its main receptors, VEGF receptor 1 (VEGFR1) and 2 (VEGFR2), are expressed in the developing central nervous system. VEGF is secreted by astrocytes and binds to endothelial receptors, which activate downstream signaling pathways to regulate angiogenesis (Rosenstein et al., 2010). In humans, at least five variant VEGF isoforms exist, including VEGF-121/145/165/189/206, each of which differs in amino acid length (Finley and Popel, 2012). VEGF-165, a pro-angiogenic isoform of VEGF-A, participates in the process of angiogenesis as the most abundant isoform of VEGF (Nakatsu et al., 2003; Ved et al., 2017).

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenously produced molecule and neurotransmitter of the indolamine family. It is primarily synthesized and secreted from the pineal gland and depends on circadian rhythms, with peak expression normally occurring at night. Melatonin is also produced in other extrapineal tissue sites, such as the retina, testes, ovaries, and skin (Huether, 1993; Söderquist et al., 2015; Ng et al., 2017; Hinojosa-Godinez et al., 2019; Lü et al., 2020). Melatonin has many physiological functions and plays a vital role in protecting the central nervous system from oxidants, inflammation, apoptosis, and toxic exposure. This role is supported by previous studies reporting that melatonin supplementation rescues memory impairment and synaptic dysfunction in Aβ1–42-treated rats (Zhang et al., 2016) and transgenic AD mice (Peng et al., 2013). Recently, it has been demonstrated that melatonin attenuates cardiac microvascular ischemia/reperfusion injury by sustaining microvascular perfusion and reducing endothelial cell death (Wang et al., 2017a; Zhou et al., 2018). Therefore, research into the mechanism by which melatonin regulates microvascularization is needed. Additionally, the protective role of melatonin on Aβ1–42-induced microvessel changes needs to be clarified.

Materials and Methods

Animals

In this study, 24 specific-pathogen-free male Sprague-Dawley rats, aged 8 weeks and weighing 290–340 g, were purchased from Vital River Laboratory Animal Technology Company (Beijing, China; SCXK (Jing) 2016-0008). The rats were kept under a 14-hour/10-hour light/dark cycle with adequate food and water. All animal procedures were approved by the Animal Care and Use Committee of Jinzhou Medical University, China (approval No. 20190105) on December 6, 2018. The rats were randomly divided into four groups (n = 6 per group): the sham (sham treatment), AD (Aβ administration), AD + melatonin (Aβ administration + melatonin treatment), and melatonin (melatonin treatment) groups.

Model establishment and drug intervention

Briefly, lyophilized Aβ1–42 peptide (Cat# A9810; Sigma-Aldrich, St. Louis, MO, USA) was incubated at 37°C for 24 hours before being dissolved in sterile, double-distilled water to a final concentration of 200 μM. The preparation was centrifuged at 14,000 x g at 4°C for 10 minutes. Finally, the soluble Aβ oligomers, which were in the supernatant solution, were collected and stored at −20°C.

The soluble Aβ oligomers were administrated by intracerebroventricular injection to generate the AD rat model (Zhang et al., 2016). Rats were anesthetized using 1% pentobarbital sodium (40 mg/kg, intraperitoneal injection). A cranial drill was used to punch a hole in the left skull, and the guide cannula (CMA 12 Elite Microdialysis Probe; CMA Microdialysis AB, Solna, Sweden) was embedded using the bregma point as the origin point (ML = ±1.7 mm, AP = −0.7 mm, and DV = −4.0 mm). The sham group was administered an intracerebroventricular injection of 5 μL saline. The AD and AD + melatonin groups were injected with 5 μL Aβ oligomers (80 μM) at a speed of 1 μL/min, and the needle was left in place for 5 minutes after the injection. Aβ1–42 was injected six times: once every other day. The melatonin and AD + melatonin groups were administered 30 mg/kg melatonin (dissolved in 25% ethanol) via intraperitoneal injection for 13 continuous days, at 16:00 each day. A 25% ethanol solution (30 mg/kg) was administered to the sham group. The procedures are depicted in a flow chart in Figure 1.

Morris water maze test

The spatial learning and memory of the rats was assessed using the Morris water maze, as described previously (Morris, 1984; Vorhees and Williams, 2006, 2014; Zhang et al., 2016), but with some modifications. When the melatonin and Aβ1–42 administration had finished, the rats performed Morris water maze testing over 6 consecutive days. The Morris water maze consists of a circular stainless-steel pool (diameter 120 cm and height 25 cm) full of water (23 ± 1°C). The pool was covered with dark green curtains, and one remote camera was fixed above the pool. The pool was divided into four quadrants by two virtual axes. A platform (diameter 7.5 cm) was placed in the middle of the northeast quadrant and submerged 1 cm below the water surface. The camera was suspended above the center of the pool to record the rats’ movements, and the video output data was digitized by the ANY-maze video tracking software (Stoelting Co., Wood Dale, IL, USA). Rats underwent four trials per day for 6 consecutive days.

The sessions on days 1–5 were conducted as navigation tests. After the initial training, the exploration test was conducted on day 6 (24 hours after the last training session). In the navigation tests on days 1 and 2, each rat was held for 15 seconds on the platform after each trial. Rats were given 60 seconds to explore the position of platform, and the time taken until they climbed onto the platform was recorded. On day 6, a 60 second exploration test was performed, where the hidden platform was removed to test their memory of the hidden platform. All data from the Morris water maze were recorded.

Pathological analysis

Rats were anesthetized using 1% pentobarbital sodium (40 mg/kg, intraperitoneal injection), and then transcardially perfused with 0.9% saline followed by 4% paraformaldehyde. Brain tissue was removed and fixed in 4% paraformaldehyde overnight, dehydrated with 30% sucrose in 4% paraformaldehyde, and then cut into 30 μm coronal sections on a vibratome (VT1200S; Leica, Wetzlar, Germany).

For histological examinations, Nissl and hematoxylin-eosin staining were used to observe morphological alterations. The sections were coated with gelatin and placed into chloroform:alcohol (1:1) overnight. The following day, the sections were dehydrated in graded ethanolos (100%, 95%). For Nissl staining, the sections were stained with 0.1% cresyl violet acetate for 5–10 minutes, quickly rinsed in distilled water, and differentiated with 95% ethyl alcohol for 2–30 minutes. Sections then were dehydrated in graded ethanolos and coverslipped with Permount™. For hematoxylin-eosin staining, the sections were rehydrated, stained with hematoxylin for 5 minutes, rinsed for 15 minutes under running water, stained in eosin for 10 seconds, and then differentiated with 1% hydrochloric acid in 75% ethanol. Sections were then dehydrated in ethanol and coverslipped with Permount™. The slices were visualized and scanned using a slide scanner (Slide Scan System SQS1000; Tekesqray, Guangzhou, China).
After three 10-minute rinses with Tris-buffered saline with 0.01% TritonX-100 and 10% normal goat serum for 1 hour at 4°C, and then incubated with the following antibodies overnight at 4°C: mouse anti-endothelial cell (RECA-1; 1:200; Cat# ab9774; Abcam, Cambridge, UK), rabbit anti-VEGF (1:1000; Cat# ab46154, Abcam), rabbit anti-VEGFR1 (1:500; Cat# sc-316; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and rabbit anti-VEGFR2 (1:1000; Cat# 9698; Cell Signaling Technology, Danvers, MA, USA). The following day, the sections underwent three 10-minute washes with Tris-buffered saline and were then incubated in the dark for 1 hour at room temperature with the following secondary antibodies: Alexa 488-conjugated goat anti-mouse IgG (1:500; Cat# A-11001; Invitrogen), Alexa 594-conjugated goat anti-rabbit IgG (1:500; Cat# A-11037; Invitrogen), and Alexa 488-conjugated donkey anti-mouse IgG (1:500; Cat# A21202; Invitrogen). After three 5-minute washes with Tris-buffered saline, the sections were incubated with 4′,6-diamidino-2-phenylindole (1: 1000; Cat# 32670, Sigma) for 5 minutes at room temperature for nuclear counterstaining. After washing with Tris-buffered saline for 10 minutes, the samples were mounted with Vectashield HardSet Antifade Mounting Medium (H-1400; Vector Laboratories, Burlingame, CA, USA) and visualized using a fluorescence microscope (DM6000; Leica).

**Results**

**Melatonin improves spatial learning and memory in AD rats**

To evaluate whether melatonin treatment modifies neuropathology and cognitive function in an AD rat model, we treated 8-week-old rats with αβ<sub>42</sub>, followed by intraperitoneal injections of melatonin. During the last week of the treatment period, the rats were tested using the Morris water maze. As has been reported previously (Oakley et al., 2006), the AD group had decreased learning and memory ability, while the sham group displayed normal learning behaviors. The AD group had greater difficulty locating the hidden platform on day 5 compared with the sham group (latency: P = 0.026; distance: P = 0.014). In contrast, the repetitive administration of melatonin significantly enhanced learning and memory ability in the AD + melatonin group compared with the AD group. The melatonin group had similar results to the sham group (Figure 2A and B). Swimming speed was similar among all groups during the trial sessions (Figure 2C).

During the probe trial, the platform was removed from the pool and the rats were made to swim for 60 seconds. Compared with the sham group, rats in the AD group made fewer line crossings (P < 0.05). Furthermore, rats in the AD + melatonin group made more line crossings than rats in the AD group (P < 0.01; Figure 2D). The time spent in the target quadrant was shorter in the AD group than in the sham group (P < 0.05), and was longer in the AD + melatonin group than in the AD group (Figure 2E). The time spent in the target quadrant by rats in the melatonin and sham groups was not significantly different. Therefore, the results of the Morris water maze revealed that melatonin can rescue the cognitive defects observed in AD rats.

**Melatonin alters αβ<sub>42</sub>-induced neuronal cell injury in AD rats**

To provide evidence of the major mechanisms of learning and memory impairment caused by αβ<sub>42</sub> administration, we used Nissl staining to examine overall changes in neuronal cell morphology in the brain. In the AD group, we observed a marked increase in cell damage, with cell shrinkage observed, as well as irregular neurons displaying hyperchromatic nuclei and dehydrated cytoplasm with many vacuoles (Ooiwaga et al., 2006; Fang et al., 2018). In the AD group, the cortical and hippocampal regions had a greater number of darkly stained cells and an increase in the gaps between cells; furthermore, nuclear pyknosis was observed. Less darkly stained cells and fewer cells with nuclear pyknosis were observed in the AD + melatonin group compared with the AD group. Neurons in the melatonin group did not have any obvious morphological changes (Figure 3A). These results demonstrated that an increase in damaged neurons might be a possible mechanism for the impaired learning and memory abilities that were induced by αβ<sub>42</sub>; this effect was alleviated by melatonin treatment.
Melatonin alleviates Aβ42-induced histological changes in the brains of AD rats.

Hematoxylin-eosin staining was also used to evaluate the effects of melatonin treatment on Aβ42-induced histological impairments (Ye et al., 2018). Intact neurons could be clearly observed in the control group. In the AD group, pyknotic nuclei and damaged neurons could be observed in the hippocampal cornu ammonis (CA) 1 region. In the AD + melatonin group, there was visible rescue of the damage induced by Aβ42. The histological results from the melatonin and sham groups were similar (Figure 3B).

Melatonin inhibits angiogenesis in Aβ42-induced AD rats.

To examine the effect of melatonin treatment on Aβ42-induced angiogenesis, we measured the expression of RECA-1, an endothelial cell marker (Ulger et al., 2002), using immunofluorescence staining. Based on the results, in the cortex, the average capillary density was lowest in the AD group and highest in the sham group. The average capillary density was higher in the AD + melatonin group compared with AD group, while no difference was observed between the melatonin and sham groups (Figure 4A and B). In the hippocampal dentate gyrus (DG) and CA3 regions, the capillary density of the AD group was the lowest among the four groups. In addition, melatonin rescued the anti-angiogenic effects of Aβ42 administration (Figure 4A, C, and E). In the hippocampal CA1 region, however, there was a different trend in capillary density. The AD group appeared to have more microvessels compared with the sham group, but this difference was not statistically significant. After melatonin treatment, the capillary density was similar to that of the sham group (Figure 4A and D).

Melatonin reduces VEGF levels in the brains of Aβ42-induced AD rats.

To investigate whether the VEGF signaling pathway plays a protective role in the inhibition by melatonin of Aβ-induced angiogenic alterations in the brain, we detected VEGF levels using western blot assay and immunofluorescence staining. Results of the western blot analysis revealed a marked increase in VEGF expression in the AD group compared with the sham group; this increase in VEGF expression was partially inhibited with melatonin treatment (Figure 5A–C). However, melatonin treatment alone significantly decreased the expression of VEGF compared with the sham group, especially in the hippocampus (Figure 5A–C). It is therefore possible that melatonin acts to bring about opposite effects to that of Aβ, perhaps via VEGF signaling. The immunofluorescence results revealed that VEGF-immunopositive staining was markedly increased in the cortex and hippocampus of rats in the AD group compared with the sham group. However, VEGF immunopositivity in the cortex and hippocampus of the AD + melatonin group appeared slightly lower than in the AD group. There was no significant difference in VEGF immunopositivity in the cortex and hippocampus between the melatonin and sham groups (Figure 5D–G).

Melatonin reduces VEGFR1 levels in the brains of Aβ42-induced AD rats.

We explored whether other components in the VEGF signaling pathway, including VEGFR1 and VEGFR2, were involved in the protective role of melatonin. Western blot analysis revealed that VEGFR1 expression in the cortex was significantly increased in the AD group compared with the sham group, and that this increase was partially reversed by melatonin. Melatonin treatment alone significantly decreased VEGFR1 expression in the cortex and hippocampus compared with the sham group, and this effect was greatest in the hippocampus (Figure 6A–C). The immunofluorescence results showed the same pattern as the western blot assay. VEGFR1 immunopositivity was markedly increased in the cortex.
that melatonin plays a protective role in Aβ toxicity in AD models (Shi et al., 2018; Karthick et al., 2019). In the present study, we repeatedly administered Aβ to impair spatial learning and memory. Aβ deposited around the vascular wall can result in vascular degeneration or reduce brain vessel density through its anti-angiogenic activity (Paris et al., 2004a, b), and this may cause memory deficits. Therefore, it is important to study the vascular changes and find a treatment to alleviate these changes. Melatonin is a hormone with high potential to protect against Aβ toxicity in AD models (Shi et al., 2018; Vincent, 2018). Previous studies have demonstrated that melatonin ameliorates blood-brain barrier integrity in AD rats. (A, B) Bands from the western blot assays for VEGF in the cortex (A) and hippocampus (B). (C) Quantitative analysis of VEGF expression by western blot assay. Data are expressed as the mean ± SEM (n = 3 per group). *P < 0.05, **P < 0.01, vs. sham group; #P < 0.05, #P < 0.01, vs. AD group; &P < 0.05, vs. AD + melatonin group (two-way repeated measures analysis of variance followed by the least significant difference post hoc tests). A+M: AD + melatonin group; AD: Alzheimer’s disease; Aβ: AD group; Aβ1–42: amyloid-beta 1–42; CA1: cornu ammonis 1; CA3: cornu ammonis 3; CX: cortex; DAPI: 4′,6-diamidino-2-phenylindole; DG: dentate gyrus; M: melatonin group; RECA-1: rat endothelial cell antibody; Sham: sham group.

Melatonin reduces VEGFR2 levels in the brains of Aβ1–42-induced rats

Next, we examined whether VEGFR2 also plays an important role in the protective effects of melatonin. Western blot analysis revealed that VEGFR2 expression levels were significantly increased in the cortex and hippocampus of the AD group compared with the sham group; this increase was partially reduced in the AD + melatonin group. Melatonin treatment alone significantly decreased VEGFR2 expression in the cortex and hippocampus compared with the sham group (Figure 7A–C). Immunofluorescence results revealed that VEGFR2 immunopositivity in the cortex and hippocampal CA1 and CA3 regions was higher in the AD group than in the sham group, and this increase was partly reversed by melatonin treatment. In contrast, there were no observable differences between the AD and sham groups in the hippocampal DG region (Figure 7D–G). It therefore seems that VEGFR2 plays a role in the cortex and the hippocampal CA1 and CA3 regions, but not in the hippocampal DG region. These results suggest that melatonin protects against Aβ1–42-induced microvascular angiogenic alterations by regulating VEGFR2 expression levels mainly in the cortex and the hippocampal CA1 and CA3 regions, but not in the hippocampal DG region.

Discussion

The deposition of Aβ peptides around cerebral vessels is one of the main pathological characteristics of AD. Various studies have shown that Aβ peptides play a role in AD pathogenesis (Mann et al., 2018; Karthick et al., 2019). In the present study, we repeatedly administered Aβ to impair spatial learning and memory. Aβ deposited around the vascular wall can result in vascular degeneration or reduce brain vessel density through its anti-angiogenic activity (Paris et al., 2004a, b), and this may cause memory deficits. Therefore, it is important to study the vascular changes and find a treatment to alleviate these changes. Melatonin is a hormone with high potential to protect against Aβ toxicity in AD models (Shi et al., 2018; Vincent, 2018). Previous studies have demonstrated that melatonin ameliorates blood-brain barrier integrity in AD rats.
Evidence regarding the interactions between Aβ peptides and microvessels suggests that they participate in the progress of AD pathology (Bell and Zlokovic, 2009; Kiong et al., 2009; Do et al., 2016). In the current study, there was decreased neural density in the cortex and hippocampus as well as prominent microvessel abnormalities in the AD group compared with the sham group. These results were consistent with those of previous studies (Ryu and McLarnon, 2009; Jantaratnotai et al., 2011) showing that Aβ1-42 animal models exhibit similar characteristics to those of AD patients, including enhanced inflammatory reactivity, neuronal loss, and altered blood-brain barrier permeability. Our study provides evidence that melatonin can reverse Aβ1-42-induced microvascular changes.

VEGF is an important factor in the remodeling of vasculature, and it also acts as a central neurotrophic factor (Dietrich et al., 2012; He et al., 2012). VEGF is involved in AD-related vascular pathology; however, VEGF expression levels differ among different studies. Some research has reported that VEGF may have a positive effect in AD models (Garcia et al., 2014; Liu et al., 2020). However, consistent with our results, the angiogenic factor VEGF was increased in AD rats in another study (Yang et al., 2004). Previous studies have reported that Aβ exerts anti-angiogenic activity both in vitro and in vivo (Paris et al., 2004b; Bridel et al., 2017). However, the specific molecular mechanism underlying this effect remains to be clarified. Thus, we studied the VEGF signaling pathway to elucidate whether the angiogenic effects of Aβ1-42 are mediated via this molecular pathway. We therefore analyzed the possible influence of Aβ on VEGFR1 and VEGFR2 expression. We revealed high expression levels of VEGF and its receptors in the cortex and hippocampus after soluble Aβ1-42 injection. Moreover, melatonin prevented the increased expression of VEGF signaling factors that was induced by Aβ1-42. Together, the results suggest that the VEGF signaling pathway is involved in the protective effects of melatonin on Aβ1-42-induced memory damage and microvascular abnormalities.

All molecules in the VEGF signaling pathway, including RECA-1, VEGF, VEGFR1, and VEGFR2, are markers of vasculature. Various studies have reported that VEGFR1 plays a central role in the AD brain and interacts with Aβ1-42. The effects of VEGFR1 and VEGFR2 remain controversial. One study has demonstrated that VEGFR1 expression increases while VEGFR2 expression decreases after Aβ1-42 injection (Singh Angom et al., 2019). However, a different study reported that VEGFR1 expression in the brain is significantly lower in AD patients than in controls (Harris et al., 2018). Moreover, other researchers showed decreased VEGFR2 expression in the brains of an AD mouse model (Cho et al., 2017). The expression of VEGFRs should therefore be further explored and discussed in the future, and the mechanisms of VEGF signaling should also be studied in more detail.

A downregulatory effect of melatonin on VEGF has been reported in neuroblastoma cells (González et al., 2017), and this finding supports our results regarding melatonin and the VEGF signaling pathway. The mechanism of action of melatonin on the effects of Aβ1-42 may be through the hypoxia-inducible factor-1α–VEGF pathway (Xu et al., 2018), such as has been investigated in retinal pathology. In future studies, we will focus on the hypoxia-inducible factor-1α–VEGF signaling pathway.

In the current study, we demonstrated that the intracerebroventricular injection of soluble Aβ1-42 oligomers is a simple and effective way to create a rat model of AD to investigate AD-associated mechanisms. We also revealed that brain vessel density may play a central role in the learning and memory deficits of AD. Furthermore, melatonin may protect against soluble Aβ1-42-mediated learning and memory deficits and changes in vessel density, possibly via VEGF and its receptors. Melatonin may therefore be a promising therapeutic agent against AD and other age-associated neurodegenerative diseases. However, further studies are required to explore the precise mechanism of melatonin in VEGF signaling regulation in AD.

In conclusion, we confirmed the protective role of melatonin against oligomeric Aβ1-42-induced impairments in spatial memory and learning. We also revealed a regulatory role of melatonin in Aβ1-42-induced microvascular changes. Finally, we demonstrated that VEGF mediates the protective effect of melatonin on microvessels via its receptors VEGFR1 and VEGFR2. In the future, we will investigate the signaling pathway that is involved in these effects, focusing especially on the downstream molecules, such as MAPK3, and the upstream hypoxia-inducible factor-1α, as well as the miRNA.
Ved N, Hulse RP, Bestall SM, Donaldson LF, Bainbridge JW, Bates DO (2017) Vascular endothelial growth factor receptor 2.

Zhang S, Wang P, Ren L, Hu C, Bi J (2016) Protective effect of melatonin on soluble amyloid-beta 1–42-induced AD rats.

Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W (2009) ABCG2 is upregulated in Alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1–40) peptides. J Neurosci 29:5463-5475.

Xu Y, Lu X, Hu Y, Yang B, Tsui CK, Yu S, Li J, Zhang L (2018) Melatonin attenuated retinal neovascularization and retinal dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice. J Pineal Res 64:e12473.

Ye T, Meng X, Zhai Y, Xie W, Wang R, Sun G, Sun X (2018) Gastrodin ameliorates Aβ1-42-induced AD rats.

Wang JC, Ahmed MM, Jiang Q, Lu NN, Tan C, Gao YP, Mahmood Q, Chen DY, Fukunaga K, Li M, Chen Z, Wilcox CS, Lu YM, Qin ZH, Han F (2017) Melatonin attenuates hypoglycemic stress-induced brain endothelial tight junction injury by inhibiting protein nitration of TP53-induced glycolysis and apoptosis regulator. J Pineal Res 63:e12440.

Wang J, Xue GX, Liu W, Shu H, Wang M, Sun Y, Liu X, Sun YE, Liu CF, Liu J, Liu W, Jin X (2017) Melatonin alleviates lipopolysaccharide-compromised integrity of blood-brain barrier through activating AMP-activated protein kinase in old mice. Aging Cell 16:414-421.

Wang Z, Zhou W, Zhou B, Zhang J (2018) Association of vascular endothelial growth factor levels in CSF and cerebral glucose metabolism across the Alzheimer’s disease spectrum. Neurosci Lett 587:276-279.

Zhang L, Yang J, Liu ZH (2018) STEP61 negatively regulates amyloid beta-mediated ERK signaling pathway in Alzheimer’s disease cell model. Zhongguo Zuzhi Gongcheng Yanjiu 22:4507-2781.

Zhang M, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachaminov A, Xu L (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333.

Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachaminov A, Xu L (2018) STEP61 negatively regulates amyloid beta-mediated ERK signaling pathway in Alzheimer’s disease cell model. Zhongguo Zuzhi Gongcheng Yanjiu 22:4507-2781.

Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachaminov A, Xu L (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333.

Zhang S, Wang P, Ren L, Hu C, BJ (2016) Protective effect of melatonin on soluble Aβ1-42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hey1 signaling pathway in the rat hippocampus. Alzheimers Res Ther 8:40.

Zhou H, Li D, Zhu P, Ma Q, Toan S, Wang J, Hu S, Chen Y, Zhang Y (2018) Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-CypD-mPTP pathway attenuates cardiac microvascular ischemia-reperfusion injury. J Pineal Res 65:e12503.

C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editors: Gardner B, Yu J, Song CP; T-Editor: Jia Y

Figure 6 | Melatonin treatment reduces VEGFR1 levels in the brains of Aβ1-42-induced AD rats.

Figure 7 | Melatonin treatment reduces VEGFR2 levels in the brains of Aβ1-42-induced AD rats.

(A, B) Bands from the western blot assays for VEGFR2 in the cortex (A) and hippocampus (B). (C) Quantitative analysis of VEGFR2 expression by western blot assay. Data are expressed as the mean ± SEM (n = 3 per group). *P < 0.05, **P < 0.01, vs. sham group; #P < 0.05, ##P < 0.01, vs. AD group; &P < 0.05, vs. AD + melatonin group (one-way analysis of variance followed by Bonferroni post hoc tests). (D–G) Immunofluorescence staining for VEGFR2 (red, stained by Alexa 594) in the cortex (D) and the hippocampal DG (E), CA1 (F), and CA3 (G) regions. VEGFR1 immunoreactivity was higher in the AD group than in the sham group, and was partially inhibited following melatonin treatment. Scale bar: 200 µm. A+M: AD + melatonin group; AD: Alzheimer’s disease; Aβ: AD group; Aβ1-42: amyloid-beta 1–42; CA1: cornu ammonis 1; CA3: cornu ammonis 3; CX: cortex; DAPI: 4′,6-diamidino-2-phenylindole; DG: dentate gyrus; HP: hippocampus; M: melatonin group; Sham: sham group; VEGFR1: vascular endothelial growth factor receptor 1.